ea0006p36 | Endocrine tumours and neoplasia | SFE2003
Chattopadhyay A
, Bhansali A
, Dash R
Gender-specific differences in tumor size at clinical presentation and possible differences in tumor biology make it important to determine treatment outcomes of male patients with bromocriptine [BRC]. We retrospectively analysed treatment response to bromocriptine in 29 male patients with macroprolactinoma (15) and giant macroprolactinoma (14). The duration of treatment was 6-96 months (mean 22.7). Clinical features at presentation included headache (21, 72.4%), visual field ...